Hey mate, no I didn't. A second little miracle entered our lives...

Hey mate, no I didn't.

A second little miracle entered our lives a few weeks ago (a little boy) so spare time, sleep, hobbies and freedom has taken a back seat.

His selling could be for any reason and it's highly unlikely anyone at the company would provide the actual answer.

SS - Totally agree that the March quarter (that should be released next week) won't be the one that will show the level of growth holders have been waiting for. There may be a token amount of international revenue and some mention that March generated an increase from delivery, messaging, Telehealth and in app purchasing. It will still be a record quarter. They consistently exceed their previous revenues Q-on-Q.

The international opportunities have been a long time in the planning and all previous announcements suggested release dates in FY20, so very close. I would hope they still go live in this timeframe so I'm holding to see the start of what a new balance sheet would like in FY21. The Patient Engagement Programs for Adheris clients is valued at $825k and set to start Q4. Revenue would be received on milestones rather than lump sum at the beginning or end, so the July quarter should show the first step.

The UK has opened up with NPA promoting MedAdvisor to all independent pharmacies so I expect there will be new customers before FY21 begins. This announcement only last month saw the share price jump from 29c to 53c.

There's also a rumble on COO that they are positioning themselves for a merger/takeover and some talk from other posters that MDR might be interested. Nick England is the only link between both companies and I'm skeptical anything will happen but will keep reading.

Anyway, back to bottles, burping, nappies and sleep deprivation.